



SHUKRA
PHARMACEUTICALS

TO,
The Dy. Gen Manager
Corporate Relationship Dept.
BSE Limited
P. J. Tower, Dalal Street,
Mumbai- 400 001

Date: 12.08.2024

Scrip Code: 524632

Dear Sir,

Sub: Outcome of Board Meeting of the Company held on August 12, 2024

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has at its meeting held on Monday, August 12, 2024, inter-alia, considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2024.

The said Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 05:00 p.m. and concluded at 6.10 p.m.

Kindly take the above on record.

Thanking you,

For, Shukra Pharmaceuticals Limited

Dakshesh Shah
Managing Director
DIN: 00561666





SHUKRA PHARMACEUTICALS

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

Rs. In Lakhs (Except EPS)

Sr.	Particulars	QUARTER ENDED			Year Ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
1	Income from Operations				
I	Revenue from Operations	317.80	1,088.39	2,016.01	7,457.29
	Less : GST Recovered	-	-	-	-
	(a) Net Sales/ Income from Operations	317.80	1,088.39	2,016.01	7,457.29
II	Other Income	71.76	137.68	63.36	281.52
	Total Income from Operations (I+II)	389.56	1,226.07	2,079.37	7,738.81
2	Expenses				
	(a) Cost of materials consumed	92.15	270.86	202.63	1,337.97
	(b) Purchase of Stock-in Trade	-	-	1,603.97	3,040.52
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	(90.48)	(108.46)	(15.58)	70.15
	(d) Employee Benefit Expenses	138.27	158.01	134.45	564.72
	(e) Finance Cost	6.17	6.98	8.46	28.50
	(g) Other Expenses	97.27	324.59	56.83	503.60
	Total Expenses	309.89	703.72	2,036.70	5,750.48
3	Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)	79.67	522.35	42.67	1,988.33
4	Exceptional Items	-	-	-	-
5	Profit / (Loss) before Extra ordinary items and Tax (3-4)	79.67	522.35	42.67	1,988.33
6	Extra ordinary items	-	-	-	-
7	Net Profit / (Loss) from Ordinary Activities before Tax(5-6)	79.67	522.35	42.67	1,988.33
8	Tax Expenses				
	I. Current Tax	26.60	125.78	-	136.16
	II. Deferred Tax	4.54	(1.79)	0.64	(1.55)
	II. Tax of Earlier Year	-	(0.23)	-	-
	IV. MAT Credit Entitlement	-	-	-	-
9	Net Profit / (Loss) for the Period (7-8)	48.53	398.59	42.03	1,853.72
10	Other Comprehensive Income (net off Tax)	-	-	-	-
	Remeasurement of defined benefit plans	-	-	-	-
	Prior Period Adjustments & Expenses	-	-	-	-
11	Total Comprehensive Income for the period (9+10)	48.53	398.59	42.03	1,853.72
12	Paid up Equity Share Capital	4,378.79	1,094.70	716.25	1,094.70
13	Face Value of Equity Shares	10.00	10.00	10.00	10.00
14	Earnings per Share (of Re. 10/- each) :				
	(a) Basic-Rs	0.11	3.64	0.59	16.93
	(b) Diluted-Rs	0.11	3.64	0.59	16.93

NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 12th August, 2024. The statutory
- The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with
- The Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- During the quarter ended 30th June, 2024, 4 complaints were received out of that 4 complaints were disposed off at the end of the quarter.
- The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
- The Company is operating in single segment, so above results are for single segment only.

For and on behalf of Board of Directors of
Shukra Pharmaceuticals Limited



Dakshesh Shah
Managing Director
DIN : 00561666

Place: Ahmedabad
Date: 12/08/2024

MAAK & ASSOCIATES


Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR MAAK and Associates
[Firm Registration No.135024W]
Chartered Accountants


Marmik Shah
Partner
Mem. No. 133926



Place : Ahmedabad
Date : 12th August, 2024
UDIN : 24133926BKCJTE9053